Business
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025 Männedorf, Switzerland, May 12, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the first quarter of 2025.On March 12, 2025, Tecan indicated a decline in sales in local currencies for the first half of the year. In line with expect
About this update from Tecan Group Ag
[{"type":"image","alt":"Tecan Group AG","displaySize":"","headline":null,"caption":"Tecan Group AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/b99e8b770148147153ad6cfc7f76d925"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iIz4lIM76opcNJpW7bTV1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b99e8b770148147153ad6cfc7f76d925","width":300,"height":105}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules","length":87,"tagName":"p"},{"type":"text","content":"Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025","length":119,"tagName":"p"},{"type":"text","content":"Männedorf, Switzerland, May 12, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the first quarter of 2025.On March 12, 2025, Tecan indicated a decline in sales in local currencies for the first half of the year. In line with expectations, sales in the first quarter declined within a mid-single-digit percentage range in local currencies. The Life Sciences Business segment delivered a solid performance, with sales in local currencies close to the prior-year level. This development was supported by increased sales into the clinical diagnostics segment, particularly for genomic testing, as well as recovering consumables sales. As expected, the Partnering Business segment recorded a slightly larger decline than the Group overall, mainly reflecting the timing of customer orders, with customers forecasting a higher volume of sales for the second half of the year. Notably, within this segment, sales of in-vitro diagnostics systems in the Synergence product line showed positive development.","length":1059,"tagName":"p"},{"type":"text","content":"While the key assumptions underlying the full-year 2025 sales outlook remain largely consistent with those communicated on March 12, 2025, Tecan provides the following update: Sales in US academic and governmental accounts continue to be impacted by uncertainty and limited visibility regarding the release of funding; accordingly, the related assumptions remain unchanged for the time being. In China, the market envir...